Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for First-Line Treatment of Patients with Squamous Non-Small Cell Lung Cancer
Go back to Ivonescimab in Combination with Chemotherapy Approved in China by NMPA for First-Line Treatment of Patients with Squamous Non-Small Cell Lung Cancer| Stratcomm Media, Ltd. (NASDAQ: SMMT) | Delayed: 17.29 -0.56 (3.14%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $17.85 | 52 Week High | $19.75 | |||
| Open | $18.40 | 52 Week Low | $4.26 | |||
| Day High | $18.42 | P/E | N/A | |||
| Day Low | $17.26 | EPS | $0.00 | |||
| Volume | 1,486,923 | |||||
